We found a protective role of a high CD8+ lymphocyte count in cHL ME: patients that recurred or experienced progression had lower amounts of CD8+ cells at diagnosis, as well as a high FOXP3/CD8 ratio, while a CD8+-enriched ME characterizes low stage of disease as compared to a ME enriched with exhausted PD1+ T-cells. The gene discussed is CD8A; the disease is classic Hodgkin lymphoma.